Concord Biotech Ltd
Concord Biotech Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks. Concord Biotech anticipates a 25% CAGR driven by: - Capacity ramp-up in injectable units. - Growth in CDMO (Contract Development and Manufacturing Organization) business. - H2 FY26 expected to show better growth compared to H2 FY25, though exact magnitude is uncertain due to external factors. - Temporary issues (EU approval delays, Middle East contract deferment, U.S.
From Concord Biotech Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks.
- Long-term target to achieve a 25% CAGR supported by new facilities, expanded product mix, and ramping up of injectable and CDMO businesses.
- Injectable facility commercialization progressing; revenues to pick up from India market initially, followed by emerging markets after 12-18 months.
- Recovery of deferred revenues from EU and Middle East contracts expected in coming quarters, mitigating recent declines.
- Positive traction in second-source opportunities and ongoing CDMO projects expected to contribute to future growth.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Concord Biotech Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The transcript does not explicitly mention any current or planned capital expenditure or strategic investments by Concord Biotech Limited in Q2 & H1 FY'26.
- However, it highlights the commissioning of a new injectable facility in March, indicating recent capital investment.
- The injectable facility is expected to ramp up commercial activity, targeting the Indian market initially, and expanding to emerging markets after 12-18 months.
- Development work in CAR-T cell therapy is underway, focusing on development for 12-15 months, which suggests ongoing R&D investment.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Concord Biotech Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Currently, Concord Biotech has one commercial CDMO project underway with sales having started and progressing well.
- Additional CDMO projects have been commercialized but are relatively small and in initial stages, serving as inroads to build larger relationships with global MNC clients.
- Discussions are ongoing with two potential innovator companies for CDMO opportunities; one was temporarily on hold due to external tariff issues but has now resumed with renewed engagement.
- Visibility on full-year CDMO revenues and orderbook clarity is expected next year as products launch and ramp-up occurs.
2 more points management made on order book & pipeline
Concord Biotech Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹278 Cr, net profit ₹68 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Concord Biotech's management said in earlier quarters
- Q3 FY25 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Concord Biotech Ltd Q2 FY26 results?
Expected stronger revenue performance in H2 FY26 compared to H2 FY25, with growth anticipated to recover from timing-related setbacks. Concord Biotech anticipates a 25% CAGR driven by: - Capacity ramp-up in injectable units. - Growth in CDMO (Contract Development and Manufacturing Organization) business. - H2 FY26 expected to show better growth compared to H2 FY25, though exact magnitude is uncertain due to external factors. - Temporary issues (EU approval delays, Middle East contract deferment, U.S.
What is Concord Biotech Ltd share price analysis?
Concord Biotech Ltd currently shows a neutral. The stock trades at a P/E of 51.0 with a market cap of ₹14,489 Cr. Investors should review the full earnings analysis for detailed insights.
Is Concord Biotech Ltd planning capital expenditure?
The transcript does not explicitly mention any current or planned capital expenditure or strategic investments by Concord Biotech Limited in Q2 & H1 FY'26.
Keep Concord Biotech Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.